!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
News|Articles|July 23, 2009
Oncology NEWS International
- Oncology NEWS International Vol 18 No 7
- Volume 18
- Issue 7
Bristol-Myers Squibb launches leukemia website
Patients with chronic myeloid leukemia can learn more about the disease at a new educational Web portal.
Advertisement
Patients with chronic myeloid leukemia can learn more about the disease at a new educational Web portal.
MyCMLCare.com offers downloadable information on CML symptoms, recommended treatment goals, tests, and side effects as well as other resources for disease management.
Articles in this issue
about 17 years ago
Less is more when it comes to serial CA125 testing in ovarian cancerabout 17 years ago
Treatment varies widely in chronic myeloid leukemiaabout 17 years ago
Oncology takes blame for rising healthcare costabout 17 years ago
Healthcare advocates call for universal coverage, acknowledge challengesabout 17 years ago
NSABP chair admits ‘failure’ in C-08 trial, denies defeatAdvertisement
Related to this article
Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5